s for its visionary decision to sponsor pre-clinical studies of tafenoquine in Candida spp, specifically targeting Candida auris. Candida auris, an emerging and incredibly drug-resistant fungal infection, poses a significant threat to global healthcare systems, causing severe infections, particularly in hospitalized patients. By exploring tafenoquine’s potential in combating Candida spp, 6... | CSIMarket News
s for its visionary decision to sponsor pre-clinical studies of tafenoquine in Candida spp, specifically targeting Candida auris. Candida auris, an emerging and incredibly drug-resistant fungal infection, poses a significant threat to global healthcare systems, causing severe infections, particularly in hospitalized patients. By exploring tafenoquine’s potential in combating Candida spp, 6...
Published |
Modified CSIMarket Newsroom | CSIMarket.com
FDA Provides Positive Feedback on Tafenoquine-Babesiosis Clinical Trial Protocol; Promising Research Partnership Announced
In a significant development for the biotechnology industry, 60 Degrees Pharmaceuticals (60P) has recently received positive feedback from the U.S. Food and Drug Administration (FDA) regarding their tafenoquine-babesiosis clinical trial protocol. Despite concerns that considerable changes would be required, the FDA has surprisingly requested no material changes, allowing the trial planning and execution to proceed as initially planned. This news brings immense relief and excitement to 60P, further bolstering their commitment to revolutionizing the treatment landscape for this debilitating and life-threatening disease.
Moreover, 60P is also making
Source for this article: Based on 60 Degrees Pharmaceuticals Inc ’s official statement
Comments